文献速递妇科

用于卵巢癌治疗的人源化亲和力成熟EGFL6抗体的制备与表征

Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy.
PubMed 文献 · Gynecol Oncol · 2023-02-17

本研究将鼠源EGFL6抗体经CDR移植人源化并亲和力成熟,筛选出可阻断EGFL6活性的抗体,在体外抑制癌细胞迁移、增殖及ERK磷酸化,并在EGFL6表达的患者来源卵巢癌异种移植瘤中限制肿瘤生长、抑制血管生成并促进凋亡,支持其进入首次人体临床试验。

要点

  • 人源化亲和力成熟EGFL6抗体对EGFL6亲和力为150 pM至2.67 nM。
  • 两个先导抗体体外抑制EGFL6介导的癌细胞迁移、增殖及ERK磷酸化升高。
  • 两个先导抗体均限制EGFL6表达的卵巢癌患者来源异种移植瘤生长。

核心结论

  • 研究证实这些人源化亲和力成熟抗体能中和EGFL6并作为治疗药物限制癌症生长,支持其开展首次人体临床试验。

研究设计与样本

  • 将选定的鼠源EGFL6抗体经CDR移植人源化,创建26种变异人源化抗体并筛选,先导候选抗体经亲和力成熟,获得7种人源化亲和力成熟EGFL6抗体。

主要发现

  • 人源化亲和力成熟抗体对EGFL6表现出高亲和力,范围为150 pM至2.67 nM。
  • 数种人源化亲和力成熟EGFL6抗体特异性结合重组及天然人EGFL6。
  • 两个先导抗体在体外抑制EGFL6介导的癌细胞迁移、增殖及癌细胞中ERK磷酸化升高。
  • 两个先导抗体均限制EGFL6表达的卵巢癌患者来源异种移植瘤的生长。
  • 对治疗的人肿瘤异种移植瘤分析显示,抗EGFL6治疗抑制血管生成、抑制肿瘤细胞增殖并促进肿瘤细胞凋亡。

关键数值与推荐

  • 7种人源化亲和力成熟EGFL6抗体被筛选其体外阻断癌细胞上EGFL6活性的能力,其中2种被选中并在体内测试治疗活性。
  • 人源化亲和力成熟抗体对EGFL6的亲和力为150 pM至2.67 nM。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Epidermal growth factor EGF-like domain multiple-6 (EGFL6) is highly expressed in high grade serous ovarian cancer and promotes both endothelial cell proliferation/angiogenesis and cancer cell proliferation/metastasis. As such it has been implicated as a therapeutic target. As a secreted factor, EGFL6 is a candidate for antibody therapy. The objectives of this study were to create and validate humanized affinity-matured EGFL6 neutralizing antibodies for clinical development. METHODS: A selected murine EGFL6 antibody was humanized using CDR grafting to create 26 variant humanized antibodies. These were screened and the lead candidate was affinity matured. Seven humanized affinity-matured EGFL6 antibodies were screened for their ability to block EGFL6 activity on cancer cells in vitro, two of which were selected and tested their therapeutic activity in vivo. RESULTS: Humanized affinity matured antibodies demonstrated high affinity for EGFL6 (150 pM to 2.67 nM). We found that several humanized affinity-matured EGFL6 antibodies specifically bound to recombinant, and native human EGFL6. Two lead antibodies were able to inhibit EGFL6-mediated (i) cancer cell migration, (ii) proliferation, and (iii) increase in ERK phosphorylation in cancer cells in vitro. Both lead antibodies restricted growth of an EGFL6 expressing ovarian cancer patient derived xenograft. Analysis of treated human tumor xenografts indicated that anti-EGFL6 therapy suppressed angiogenesis, inhibited tumor cell proliferation, and promoted tumor cell apoptosis. CONCLUSIONS: Our studies confirm the ability of these humanized affinity-matured antibodies to neutralize EGFL6 and acting as a therapeutic to restrict cancer growth. This work supports the development of these antibody for first-in-human clinical trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Tang H, Fayomi AP, Bai S, et al. Generation and characterization of humanized affinity-matured EGFL6 antibodies for ovarian cancer therapy. Gynecol Oncol. 2023. PMID: 36804621. doi:10.1016/j.ygyno.2023.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。